Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA.
J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):9-15. doi: 10.1093/gerona/glac169.
In this study, we examined the link between plasma Alzheimer's disease (AD) biomarkers and physical functioning outcomes within a community-dwelling, multiethnic cohort. Data from 1 328 cognitively unimpaired participants (n = 659 Mexican American and n = 669 non-Hispanic White) from the ongoing Health & Aging Brain Study-Health Disparities (HABS-HD) cohort were examined. Plasma AD biomarkers (amyloid beta [Aβ]40, Aβ42, total tau [t-tau], and neurofilament light chain [NfL]) were assayed using the ultra-sensitive Simoa platform. Physical functioning measures were the Timed Up and Go (TUG) and the Short Physical Performance Battery (SPPB). Cross-sectional linear regression analyses revealed that plasma Aβ 40 (p < .001), Aβ 42 (p = .003), and NfL (p < .001) were each significantly associated with TUG time in seconds. Plasma Aβ 40 (p < .001), Aβ 42 (p < .001), t-tau (p = .002), and NfL (p < .001) were each significantly associated with SPPB Total Score. Additional analyses demonstrate that the link between plasma AD biomarkers and physical functioning outcomes were strongest among Mexican Americans. Plasma AD biomarkers are receiving a great deal of attention in the literature and are now available clinically including use in clinical trials. The examination of AD biomarkers and physical functioning may allow for the development of risk profiles, which could stratify a person's risk for neurodegenerative diseases, such as AD, based on plasma AD biomarkers, physical functioning, ethnicity, or a combination of these measures prior to the onset of cognitive impairment.
在这项研究中，我们在一个居住在社区的、多种族队列中研究了血浆阿尔茨海默病 (AD) 生物标志物与身体功能结果之间的联系。检查了正在进行的健康与衰老大脑研究-健康差异 (HABS-HD) 队列中 1328 名认知正常的参与者的数据（n=659 名墨西哥裔美国人和 n=669 名非西班牙裔白人）。使用超灵敏 Simoa 平台检测血浆 AD 生物标志物（Aβ40、Aβ42、总 tau [t-tau] 和神经丝轻链 [NfL]）。身体功能测量包括计时起立行走 (TUG) 和简短身体表现电池 (SPPB)。横断面线性回归分析显示，血浆 Aβ40（p<0.001）、Aβ42（p=0.003）和 NfL（p<0.001）与 TUG 时间（秒）均呈显著相关。血浆 Aβ40（p<0.001）、Aβ42（p<0.001）、t-tau（p=0.002）和 NfL（p<0.001）与 SPPB 总评分均呈显著相关。进一步的分析表明，血浆 AD 生物标志物与身体功能结果之间的联系在墨西哥裔美国人中最强。血浆 AD 生物标志物在文献中受到极大关注，现在临床上也可以获得，包括在临床试验中使用。AD 生物标志物和身体功能的检查可以允许开发风险概况，这可以根据血浆 AD 生物标志物、身体功能、种族或这些措施的组合，在认知障碍发生之前，对一个人患神经退行性疾病（如 AD）的风险进行分层。
